- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07280156
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE) (RELEASE)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Efficacy, Safety, and Dosing Regimen Selection of Multiple Intravenous Infusions of PRX-115 With and Without Methotrexate Versus Placebo in Adult Patients With Gout (RELEASE)
This is a multicenter, randomized, double-blind, placebo-controlled phase II study assessing the efficacy, safety, and dosing regimen selection of multiple IV infusions of PRX-115 over 24 weeks, with or without MTX, versus the respective placebos in adult patients with gout.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will evaluate the efficacy, safety, tolerability, immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD) of PRX-115 (a recombinant pegylated Uricase) in adult patients with gout. Participants will receive PRX-115 by intravenous (IV) infusions according to different treatment schedules, with and without the immunomodulator methotrexate (MTX).
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Head of Clinical Development
- Phone Number: +972-4-902-8100
- Email: info@protalix.com
Study Locations
-
-
-
Tbilisi, Georgia, 0102
- Recruiting
- Aleksandre Aladashvili Clinic LLC, Georgia
-
Tbilisi, Georgia, 0159
- Recruiting
- Tbilisi Heart and Vascular Clinic Ltd , Georgia
-
Tbilisi, Georgia, 0160
- Recruiting
- Mediclub Georgia
-
Tbilisi, Georgia, 0160
- Recruiting
- Tbilisi Institute of Medicine, Georgia
-
Tbilisi, Georgia, 0172
- Recruiting
- Georgian-Dutch Hospital, Georgia
-
Tbilisi, Georgia, 0180
- Recruiting
- LTD First Medical Center, Georgia
-
-
-
-
-
Afula, Israel, 1834111
- Recruiting
- HaEmek MC, Israel
-
Ashkelon, Israel, 7830604
- Recruiting
- Barzilai MC, Israel
-
Kfar Saba, Israel, 4438164
- Recruiting
- Meir MC, Israel
-
-
-
-
Arizona
-
Glendale, Arizona, United States, 85306
- Recruiting
- Rezen Clinical Trials
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Recruiting
- Applied Research Center of Arkansas
-
-
California
-
Anaheim, California, United States, 92805
- Recruiting
- Advanced Research Center, Inc
-
El Cajon, California, United States, 91910
- Recruiting
- Triwest Research Associates Llc
-
La Palma, California, United States, 90623
- Recruiting
- Imax Clinical Trials, LLC
-
Long Beach, California, United States, 90806
- Recruiting
- Kinetic Clinical Research
-
-
Florida
-
Clearwater, Florida, United States, 33765
- Recruiting
- Clinical Research of West Florida, Inc.
-
DeLand, Florida, United States, 32720
- Recruiting
- Accel Research Sites - Deland Clinical Research Unit
-
Doral, Florida, United States, 33125
- Recruiting
- ICR Sites East
-
Hialeah, Florida, United States, 33010
- Recruiting
- Qway Research
-
Miami, Florida, United States, 33155
- Recruiting
- Bioclinical Research Alliance, Inc
-
Miami, Florida, United States, 33169
- Recruiting
- D&H National Research Centers (North Miami)
-
Miami, Florida, United States, 33173
- Recruiting
- Well Pharma Medical Research Group
-
Orlando, Florida, United States, 32832
- Recruiting
- Conquest Research - Lake Nona
-
Orlando, Florida, United States, 32897
- Recruiting
- Combined Research Orlando Phase I-IV
-
Palmetto Bay, Florida, United States, 33176
- Recruiting
- New Horizons Research
-
Tampa, Florida, United States, 33606
- Recruiting
- Clinical Research of West Florida, Inc.
-
-
Georgia
-
Columbus, Georgia, United States, 31904
- Recruiting
- Centricity Research - Columbus Georgia Multispecialty
-
-
Michigan
-
Dearborn, Michigan, United States, 48126
- Recruiting
- Revival Research Institute, LLC
-
Farmington Hills, Michigan, United States, 48334
- Recruiting
- Quest Research Institute
-
Sterling Heights, Michigan, United States, 48313
- Recruiting
- Revive Research Institute, Inc
-
-
Pennsylvania
-
Duncansville, Pennsylvania, United States, 16635
- Recruiting
- Altoona Center for Clinical Research
-
-
Texas
-
Houston, Texas, United States, 77099
- Recruiting
- Pioneer Research Solutions Inc
-
Sugar Land, Texas, United States, 77479
- Recruiting
- Mt. Olympus Medical Research, LLC - Sugar Land
-
Waco, Texas, United States, 76710
- Recruiting
- Velocity Clinical Research
-
-
Virginia
-
Suffolk, Virginia, United States, 23435
- Recruiting
- Velocity Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males or females ≥18 years of age.
- Weight within the range of 50.0 - 150.0 kg.
- Gout patients who failed to normalize sUA (<7 mg/dL) with or without xanthine oxidase inhibitors or uricosuric agent or have contraindications to these drugs.
- Willing to discontinue any oral ULT
- Females who are sterile, postmenopausal, or non-pregnant and using birth control methods.
Exclusion Criteria:
- Any condition known to have arthritis as a clinical manifestation.
- Positive testing for HBV,HCV, or HIV.
- The patient is a pregnant or lactating female or plans to become pregnant during the study period.
- Known allergy or sensitivity to the injected proteins, including pegylated products.
- Prior exposure to any experimental or marketed uricase.
- Patient treated with a medication known to have an influence on urate metabolism or clearance such as ULTs.
- History of anaphylaxis, severe allergic reactions, or severe atopy.
- G6PD deficiency or known catalase deficiency.
- History of significant hematologic or autoimmune disorders within 5 years of Screening and/or patient is immunocompromised or treated with immunosuppressive medications.
- Non-compensated CHF or hospitalization for CHF (Stage 3-4 NYHA Functional Class) within 3 months of the Screening Visit, uncontrolled arrhythmia, treatment for acute coronary syndrome (myocardial infarction or unstable angina), or uncontrolled BP (>160/100 mmHg) at screening and prior to randomization at Week -4 (Visit 1).
- Current liver disease, as determined by ALT or AST levels above upper limit of normal at Screening Visit.
- Chronic liver disease.
- Hemoglobin <11 g/dL, neutrophil count <1500 /µl, or platelet count <100,000 /µl.
- Known severe pulmonary fibrosis, bronchiectasis or interstitial pneumonitis.
- eGFR ≤ 40 mL/min/1.73m2 tested at Screening Visit. Kidney transplant or requires dialysis.
- Known intolerance and/or known contraindication to MTX treatment or MTX treatment considered inappropriate
- Has uncontrolled type 2 diabetes at Screening with HbA1c ≥8.5%. Patients with type 1 diabetes will be excluded.
- Has known latent autoimmune diabetes of adult.
- Immunocompromised state, regardless of etiology.
- History or treatment of malignancy in the last 5 years, excluding localized, nonmelanoma skin cancers (e.g. basal or squamous cell)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: E4W with placebo-MTX
IV infusion of PRX-115 every 4 weeks (E4W) for a total of 6 doses with placebo-MTX |
intravenous (IV) infusion Oral Placebo-MTX weekly |
|
Experimental: E4W with MTX
IV infusion of PRX-115 every 4 weeks (E4W) for a total of 6 doses with MTX |
intravenous (IV) infusion Oral MTX 15 mg weekly |
|
Experimental: E6W with MTX
IV infusion of PRX-115 every 6 weeks (E6W) for a total of 4 doses with MTX |
intravenous (IV) infusion Oral MTX 15 mg weekly |
|
Experimental: E8W with MTX
IV infusion of PRX-115 every 8 weeks (E8W) for a total of 3 doses with MTX |
intravenous (IV) infusion Oral MTX 15 mg weekly |
|
Placebo Comparator: placebo E4W
infusion of PRX-115 placebo every 4 weeks (E4W) for a total of 6 doses with placebo-MTX |
Oral Placebo-MTX weekly intravenous (IV) infusion |
|
Placebo Comparator: placebo E6W
IV infusion of PRX-115 placebo every 6 weeks (E6W) for a total of 4 doses with placebo-MTX |
Oral Placebo-MTX weekly intravenous (IV) infusion |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6
Time Frame: 6 months of treatment
|
Proportion of patients who achieve a reduction in sUA to <6.0 mg/dL for at least 80% of the time during Month 6 |
6 months of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) at different time points
Time Frame: 3 to 6 months of treatment
|
Proportion of patients that achieve a reduction in sUA to <6.0 mg/dL for at least 80% of the time during Month 3 or 4, 5 and 6. |
3 to 6 months of treatment
|
|
Treatment-emergent adverse events (TEAEs)
Time Frame: From enrollment to 8 months of study
|
Occurrence and severity of treatment-emergent adverse events (TEAEs) |
From enrollment to 8 months of study
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Crystal Arthropathies
- Musculoskeletal Diseases
- Pathologic Processes
- Arthritis
- Joint Diseases
- Rheumatic Diseases
- Purine-Pyrimidine Metabolism, Inborn Errors
- Metabolism, Inborn Errors
- Genetic Diseases, Inborn
- Metabolic Diseases
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Gout
- Hyperuricemia
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Pterins
- Pteridines
- Aminopterin
- Methotrexate
Other Study ID Numbers
- PB115-GT-201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.